| C A S E REP ORT
A 62 year old male with end stage chronic obstructive pulmonary disease underwent bilateral lung transplant, which was complicated by coagulopathy requiring temporary chest closure. He returned to the operating room on postoperative day 1 for hemothorax evacuation, and on postoperative day 2 for delayed closure of the thoracosternotamy. Induction immunosuppression included basiliximab (20 mg on day 0 and 4) and methylprednisolone (initial dose 125 mg every 8 hours x 2 doses, then tapered), after which he was maintained on tacrolimus (goal troughs 10-15 ng/mL), mycophenolate mofetil (1000 mg twice daily) and prednisone. Due to persistent delirium following transplantation, the tacrolimus was discontinued and cyclosporine started (goal concentration 225-260 ng/mL) on postoperative day 11.
The patient had been initiated on empiric piperacillin-tazobac- By postoperative day 33, the blood ammonia level had normalized to 40. The patient was alert and following simple commands.
Doxycycline was continued but additional therapies to lower ammonia levels were discontinued. The patient continued to improve without relapse of hyperammonemia.
| D ISCUSS I ON
Idiopathic hyperammonemia has been reported to occur in 0.5%-4.1% of lung transplant recipients. 5 It has been defined as elevated plasma ammonia concentrations, >200 μmol/L, in the absence of significant liver dysfunction. 6 Patients typically present with mental status changes. Among solid organ transplants, this syndrome most commonly affects lung transplant recipients, although has been reported in heart, combined heart-lung, and renal transplant recipients. 5 Total parenteral nutrition, gastrointestinal complications and lung transplantation for primary pulmonary hypertension have been associated with increased risk for this syndrome in lung transplant patients. 1 Idiopathic hyperammonemia has also been reported following bone marrow transplantation, and in individuals receiving chemotherapy. 6 Disseminated Ureaplasma species infection was first reported as a cause of idiopathic hyperammonemia among lung transplant recipients in 2015. 2 The genera Ureaplasma consists of 2 human species, urealyticum and parvum, and belongs to the class Mollicutes.
Ureaplasma produce the enzyme urease, which hydrolyzes urea into the products ammonia (NH 3 ) and carbon dioxide (CO 2 ). While a number of bacteria produce urease, Ureaplasma is unique in requiring hydrolysis of urea for nearly all ATP generation. This ATP synthesis is thought to be dependent on an ammonia chemical potential generated through urea hydrolysis. In addition, the U. urealyticum urease has also been shown to be a much more potent energy producer than other bacterial ureases. found to be of a significantly younger age, were all reported to be sexually active with multiple sexual partners, and all had documented aspiration events. The authors hypothesized that sexual activity may increase the risk for oral cavity colonization of Ureaplasma species, which may then be introduced into the lungs during aspiration. 8 At our hospital, testing for Ureaplasma species from donor BAL is not routinely done, and was not performed in our case.
Ureaplasma species may cause hyperammonemia syndrome in individuals immunocompromised due to etiologies other than lung transplantation. Recently, U. parvum was identified by tracheal aspirate PCR in a bone marrow transplant recipient with hyperammonemia syndrome. The patient's ammonia levels and mental status improved after starting Ureaplasma-directed antimicrobials. Treatment options may include tetracycline, macrolide and fluoroquinolone antibiotics, although resistance has been reported to all of these classes. 13 In this case report, the patient had already improved on empiric doxycycline before the positive BAL culture was available, and antimicrobial susceptibilities were not obtained.
Potential strategies for prevention in lung transplant recipients that have been proposed, and warrant further study, include universal screening of donors and recipients for Ureaplasma species, treatment of proven infections vs universal prophylaxis pending results, and systemic post-transplant monitoring of ammonia levels in lung transplant recipients. 8 Given the potential for antimicrobial resistance, prolonged time to culture confirmation, and high mortality with this syndrome, empiric therapy with two Ureaplasma directed antimicrobials may be warranted.
In summary, this case adds to the growing literature that
Ureaplasma species are an important cause of hyperammonemia syndrome post-lung transplant, and that early directed treatment can be associated with good outcomes. 
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